ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

ClinicalTrials.gov ID: NCT07037420

Public ClinicalTrials.gov record NCT07037420. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 17, 2026, 6:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination With Somatostatin Analogs in Adult Participants With Acromegaly

Study identification

NCT ID: NCT07037420
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Enrollment: 60 participants

Conditions and interventions

Conditions

Acromegaly

Interventions

ALXN2420 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 27, 2025
Primary completion: Jan 7, 2027
Completion: Nov 10, 2027
Last update posted: Apr 6, 2026

2025 – 2027

United States locations

U.S. sites: 9
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
Research Site	Los Angeles	California	90048	Recruiting
Research Site	Los Angeles	California	90095	Recruiting
Research Site	Torrance	California	90502	Recruiting
Research Site	Aurora	Colorado	80045	Withdrawn
Research Site	Boston	Massachusetts	02114	Recruiting
Research Site	Ann Arbor	Michigan	48109	Recruiting
Research Site	Las Vegas	Nevada	89148	Recruiting
Research Site	New York	New York	10032	Recruiting
Research Site	Portland	Oregon	97239	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07037420, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 6, 2026 · Synced May 17, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07037420 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →